Argos Therapeutics Inc., a Durham, North Carolina-based biopharmaceutical company focused on the development and commercialization of immunotherapies, secured $42.5m in Series E financing.
The round was led by Pharmstandard International S.A. (Luxembourg), with participation from Green Cross Corporation of Seoul, Korea (006280:Korean Stock Exchange), and existing investors Forbion Capital, TVM Capital, Lumira Capital, Intersouth Partners, Caisse de depot et placement de Quebec, Morningside Group and Aurora Funds.
Led by Jeff Abbey, President and Chief Executive Officer, Argos Therapeutics leverages its Arcelis™ technology platform to develop personalized immunotherapies for the treatment of cancer and infectious diseases. Its most advanced product candidate is AGS-003, which has initiated a pivotal Phase 3 study for the treatment of metastatic renal cell carcinoma (mRCC).
The company, which intends to use the funds for its Phase 3 clinical study of AGS-003, also plans to have data from its Phase 2b study of AGS-004 for the treatment of HIV in the first half of 2014.